[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569836":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":29,"locations":35,"responsibleParty":69,"collaborators":11,"id":73,"slug":11,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":74,"sex":80,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":11,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":11,"overallStatus":50,"whyStopped":11,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Qilu Hospital of Shandong University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Qishenyiqi Dripping Pill","EXPERIMENTAL",null,[13],"Drug: Qishenyiqi dripping pills 1 bag, three times a day",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo","PLACEBO_COMPARATOR",[18],"Drug: Placebo 1 bag, three times a day",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Qishenyiqi dripping pills 1 bag, three times a day","Qishenyiqi dripping pills, 1 bag once, three times a day, 12 months",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Placebo 1 bag, three times a day","Placebo, 1 bag once, three times a day, 12 months",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":11,"email":34},"Panpan Hao, Dr.","CONTACT","8618560086593","panda.how@sdu.edu.cn",[36,49,58],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":11},"Qianfoshan Hospital, Shandong University","ACTIVE_NOT_RECRUITING","Jinan","Shandong","250012","China",{"type":44,"coordinates":45},"Point",[46,47],116.99722,36.66833,{"lat":47,"lon":46},{"facility":5,"status":50,"city":39,"state":40,"zip":41,"country":42,"cosmosGeoPoint":51,"geoPoint":53,"contacts":54},"RECRUITING",{"type":44,"coordinates":52},[46,47],{"lat":47,"lon":46},[55],{"name":56,"role":32,"phone":57,"phoneExt":11,"email":34},"Panpan Hao, Dr","18560086593",{"facility":59,"status":50,"city":39,"state":40,"zip":60,"country":42,"cosmosGeoPoint":61,"geoPoint":63,"contacts":64},"Jinan Central Hospital Affiliated to Shandong First Medical University","250031",{"type":44,"coordinates":62},[46,47],{"lat":47,"lon":46},[65],{"name":66,"role":32,"phone":67,"phoneExt":11,"email":68},"Bin Li, Dr","13370586671","qingquan0615@163.com",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Pan-Pan Hao","Prof.","100569836",false,"NCT06699420","Qishenyiqi Dripping Pill for Coronary Microvascular Disease","The Efficacy and Safety of Qishenyiqi Dripping Pill in Patients With Coronary Microvascular Disease","CMVD","Inclusion Criteria:\n\n* Repeated chest pain attacks with typical exertional angina pectoris or resting angina pectoris attacks;\n* Coronary normal or stenosis \\\u003C 20%;\n* Ischemic depression in ST segment during resting or exercise;\n* Blood flow reserve (CFR) of the anterior descending coronary artery \\\u003C 2.0;\n* Subjects or their guardians agreed to participate in this study.\n\nExclusion Criteria:\n\n* Previous myocardial infarction or PCI or CABG treatment;\n* A history of heart failure;\n* Severe arrhythmia;\n* Refractory hypertension or hypertension accompanied by left ventricular wall thickness \\> 12 mm;\n* Familial hypercholesterolemia;\n* Takayasu arteritis, Kawasaki disease or coronary artery malformation;\n* Pregnant or nursing, or having the intention to give birth within one year;\n* Hepatic or renal dysfunction;\n* Allergic to contrast agents or traditional Chinese medicines;\n* Patients who participated in clinical research of other drugs within 3 months before being selected.","ALL","40 Years","75 Years",{"count":84,"type":85},162,"ESTIMATED","INTERVENTIONAL",[88],"PHASE4","To investigate the efficacy and safety of Qishenyiqi in patients with microvascular angina pectoris. Long-term follow-up of 1 year will be performed to evaluate the effect of Qishenyiqi on coronary flow reserve and adverse cardiovascular events in patients with coronary microvascular disease.",[91],"Coronary Microvascular Disease","2024-11-20",{"date":94,"type":95},"2024-11-21","ACTUAL",{"date":97,"type":95},"2023-11-08",{"date":99,"type":85},"2026-06-30",{"name":5,"class":6},3]